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Background: Scaffolds are one of the three most important elements constituting the basic concept of
regenerative medicine, and are included in the core technology of regenerative medicine along with stem cells and
tissue engineering. Stem cells are very important technology because they are directly responsible for the
regenerative treatment of the disease and the damaged tissue, but with regards to the technology and the
products that use stem cells exclusively, there is a technical limitation of limited survival rate and the engraftment
rate of the transplanted cell, and rather than recovering the damaged tissue fundamentally, there is a limit that the
concept is more of just another medicine treatment using cells.
A scaffold is a natural or synthetic biocompatible material transplanted into a human body to be used as the
exclusive treatment or as an assisted method of another treatment of a disease and for the recovery of damaged
tissue. Therefore, according to the characteristics of the tissue to be applied, scaffolds must have the characteristics
such as the excellent biocompatibility, biodegradability, minimum immunity and inflammation, proper mechanical
strength and interaction between the material and the cells.
Results: The world stem cell market was approximately 2.715 billion dollars in 2010, and with a growth rate of
16.8% annually, a market of 6.877 billion dollars will be formed in 2016. From 2017, the expected annual growth
rate is 10.6%, which would expand the market to 11.38 billion dollars by 2021. Meanwhile, the world scaffold
element technology market was approximately 4.57 million dollars in 2013, and by increasing 13.4% annually, it is
estimated to expand to 10.63 million dollars by 2020. The Korean scaffold element technology market was about 22
million dollars in 2013, and with a steady growth of approximately 13.4% every year, it is prospected to be about
52 million dollars by 2020.
Conclusions: In comparison to the medical material and medicine sales growth rate, the future scaffold element
technology market is judged to be higher in growth possibility.
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In the modern society, due to developments in technol-
ogy and industry, there are increasing cases of defunctio-
nalization or damage to tissues or organs from various
accidents, diseases, and aging, and as the human body
reaches its limits in self-regeneration ability, the need for
proper and effective treatment methods is increasing
rapidly [1-3].
For the treatment of damaged tissue or organs, organ
transplantation from donors or animals is often attempted,* Correspondence: jwlee@kisti.re.kr
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unless otherwise stated.but there are many problems such as a lack of organ do-
nors, immune rejection response, and animal-derived vi-
ruses [4-8]. Therefore, the tissue engineering approach of
using biomaterials to effectively substitute for or transplant
a replacement of damaged biological tissues or organs
while avoiding these problems is coming to the fore, and
thus there is a need for various studies on these research
topics [8-12].
Accordingly, studies on biomaterials useful in tissue
regeneration are actively being conducted to design ma-
terials that can induce the regeneration of the damaged
tissue or organ. Research is also currently being done on
stem cell differentiation within scaffolds and mecha-
nisms of the tissue regeneration on transplant to the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cation of its therapeutic method [13]. However, it is very
difficult to form three-dimensional artificial organ simi-
lar to the structurally complex tissue within the human
body due to the technical limits in the biomaterial
development.
Methods
Data for this research were gathered from primary and
secondary sources as well as the databases of the Korea
Institute of Science Technology Information. The key
areas of the research process are described below.
Primary research
Primary research sources relied for the databases of Korea
Institute of Science Technology Information, past industry
research service/study, economic and demographic data,
and trade and industry journals. This research was con-
ducted to map and analyze market and technology trends.
Secondary research
Secondary research was used to supplement and comple-
ment the primary research. Interviews were conducted
with physicians and surgeons from the key hospitals and
senior sale/marketing managers from cell therapy product
suppliers in South Korea.
Results and discussion
Concept and characteristics of scaffolds
Scaffolds are one of the three most important elements
constituting the basic concept of regenerative medicine,
and their role is adhesion and differentiation of the cells
disseminated inside and outside of their structure, and the
basis for providing the proper environment for cell prolif-
eration and differentiation moving from the surroundings
of the tissue and for providing the tissue form required
[14]. Also, scaffold technology is included in the core
technology of regenerative medicine along with stem cells
and tissue engineering.
Stem cells are the most important technology because
they directly take charge of regenerative therapy on the
disease and the damaged tissue [15], but it is not easy to
realize regenerative medicine’s goal of “fundamental re-
covery of the damaged tissue and organ” with stem cells
alone [16]. Currently, various types of stem cells such as
autologous and allogeneic adult stem cells, embryonic
stem cells (ESCs), and induced pluripotent stem cells are
being used in many attempts to cure disease, and for the
adult stem cells, some products have already been devel-
oped for commercialization. However, technology and
products using stem cells exclusively have technical limi-
tations due to the limited survival rate and engraftment
rate of the transplant cell, and with these limits, stem
cell treatment become more of a concept of anothermedicine treatment using cells rather than a way to re-
cover the damaged tissue fundamentally. In an attempt
to overcome this technical limit, biomaterial technology
for the transplant and delivery of stem cells and tissue
engineering technology for engrafting biomaterials are
being actively studied.
The scaffold is a natural or synthetic biocompatible
material transplanted into the human body for the treat-
ment of the disease and recovery of the damaged tissue,
used exclusively or as a means of assistance to another
treatment [14,17]. Therefore, according to the excellent
biocompatibility, biodegradability, minimum immunity
and inflammation, proper mechanical strength, inter-
action between the material and the cell, interconnected
porosity structure, and the characteristics of the tissue
to be applied, characteristics such as the proper mechan-
ical strength are required [18].
Currently, the biomaterials used clinically for the trans-
plant of stem cells are natural biomaterials such as collagen,
fibrin, chitosan, keratin, peptide, hyaluronate, hydrogel, silk
protein, hydroxyl, and tri-calcium phosphate as well as
approved medical macromolecules with biocompatibil-
ity with synthetic biomaterials such as PLA, PGA,
PLGA, and PLC [18-22]. Natural biomaterials have ex-
cellent bio-functionality such as biocompatibility and
biodegradability but have the disadvantages of limited
mechanical and physical strength and low processability.
On the other hand, synthetic biomaterials can be con-
trolled the characteristics of their excellent mechanical
property, flexible processability. Among the synthetic bio-
materials, biodegradable biomaterials that self-degrade
after inducing the regeneration and recovery of tissue in
the human body are being studied greatly.
Researchers in tissue engineering technology have
been mounting stem cells on biomaterials and cultivat-
ing them inside or outside the human body to produce
artificial organs similar in structure and function to ac-
tual human tissues or organs.
Regarding current status of the biomaterial development
technology in Korea, there are companies developing and
producing single products such as badges. Most Korean
biomaterial companies are focused on cell therapy prod-
ucts using cells rather than on producing primary cultured
cells for studies or stem cells R&D. However, in other
parts of the world, many companies are developing and
commercializing cells and cultured elements such as pri-
mary cultured cells for study, stem cells, culture mediums,
and coatings.
Characteristics of the stem cell technology industry
Scaffold technology is applied as the element in the regen-
erative medicine field, relevant to the stem cell industry
and also to the regenerative medicine industry by exten-
sion. Regenerative medicine is a high-tech convergence
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tissue and organ that is damaged or malfunctioning due
to aging, disease, and an accident. Also, regenerative
medicine is emerging as an alternative to treating in-
tractable diseases such as dementia, diabetes, and spinal
cord injury for which no proper therapy method cur-
rently exist, and it is being applied in various fields such
as customized cell therapy products, biological tissues,
and in bio-organ development. Regenerative medicine is
receiving attention as a new growth engine to create enor-
mous economic added value.
When we look at the main characteristics of the re-
generative medicine technology and industry, it first be-
comes apparent that regenerative medicine technology
mainly focuses on intractable and chronic diseases;
therefore, there is a great demand for clinical treat-
ment. Second, since unlike in the existing drug therap-
ies, the subject is a living cell, there are technical and
procedural difficulties in the process of approval. Third,
because it is mostly transplanted through surgical pro-
cesses, optimization and standardization of the clinical
protocol and new medical technology and improvement
in the health insurance system are required. Lastly,
verification of clinical safety and effectiveness through
long-term observation is very important.
The stem cell industry is a field which will likely de-
velop in various areas such as cell therapy products, new
drug developments, and bio-tissue engineering, which
will be used widely in disease treatment. Since it is a
new field that has not yet established its overall technol-
ogy system, various types of research and development are
being attempted for industrialization and performanceTable 1 Technology field and contents related to stem cells [2
Technology field Contents
Bio-tissue engineering and engineering of bio-
organs using stem cells
- The regenerative ability of
and the widely-differentiate
the treatment of the disease
- The bio-tissue using stem
to possess a big strength as
Cell therapy product development using stem
cells
- The stem cell extracted fro
injected into the relevant p
- The universality of the stem
system, the nervous system
the skin.
Efficiency of new drug development using
stem cells
- Stem cells are differentiate
drugs, and the effectiveness
efficiency of new drug deve
- During the clinical test pro
cells and tissues, which are
drug more easily and quick
- The cancer stem cell is the
diagnostic technology deve
and diagnostic agent develcreation. Due to the lack of R&D manpower and low
technology maturity in the stem cell industry, there are
many technical difficulties to overcome before actual
commercialization can occur, but depending on future
R&D efforts, the growth potential is high, and the mar-
ket entry barrier is relatively low, which means that it is
a field with high development possibility. Also, it is a
high value-added application field that is based on bio-
technology and converged with high technology such as
IT, NT, etc. The industry not only has added-value on
the medicine itself based on regenerative effects, but it
also has front and back linkage effects with the medical
industry, and high quality employment can be created
with the advanced country type knowledge-based tech-
nology. Due to the long development period and high
risk in the industrialization process, it is also a field that
is generalized by government-led R&D support world-
wide (Table 1).Korean and world scaffold market size and prospects
Regarding the market for scaffolds, which are a biomaterial
and one of the core element technologies in regenerative
medicine, the scaffolds market data is very insufficient for
clearly understanding and estimating its scope and size.
The element technology market for scaffolds has the
characteristic of high relating effect with the front in-
dustry; therefore, the market trend, size, and prospects
for scaffolds will be assumed to be similar to the trend
of the front industry, the stem cell and regenerative
medicine industry, and will be estimated using data
from that industry.3]
the stem cell is used to culture the stem cell and the supporting cells,
d tissue and organ regenerates the damaged tissue or organ to enable
.
cell is high in biocompatibility and low in immune-rejection, expected
the tissue engineering product.
m the patient is differentiated/proliferated in a specific environment and
atient to substitute for the function of the damaged cell and tissue
cell is expected to innovate in all medical fields of the cardiovascular
, the blood and immune system, the bone and cartilage system, and in
d into specific disease cells to discover candidate materials for new
verification is quickly performed in large quantities to improve the
lopment.
cess in new drug development, stem cells are differentiated into various
expected to verify the toxicity of the candidate material for the new
ly.
original material for anticancer drug development and for initial
lopment of cancer, prospected to be utilized in new anticancer drug
opment.
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and prospects for scaffold element technology, the follow-
ing data related to the stem cell market are considered.
First, total world market size, prospects, and growth
rate of the stem cell field in which scaffolds are applied
are identified. The world stem cell market was approxi-
mately 2.715 billion dollars in 2010 and with a 16.8%
growth rate annually, the market will be 6.877 billion
dollars in 2016 with an annual average growth of 10.6%
starting in 2017, the market is prospected to expand to
11.38 billion dollars by 2021 [1] (Table 2).
Second, in the stem cell market, the market size of
which scaffold element technology is included is as-
sumed. As we can see in Table 3, the element technology
field, which is classified into cell lines, cell culture fluid,
and cell carriers, occupies an average of about 10.15%
(2010 ~ 2015) of the total technology market related to
cell treatment, and from 2005 to 2015, an annual aver-
age growth rate of 17.2% is prospected [24].
Third, the world stem cell market is estimated to grow
rapidly from 1.1 billion dollars in 2012 to 16 billion dol-
lars by 2020 with an annual growth rate of 39.7%.
Within this, the world market size of the cell culture
and consumables market, including the scaffold develop-
ment technology market, was 320 million dollars in
2012 and is prospected to expand to 420 million dollars
in 2015. Also, in 2011, the Korean sales related to stem
cells make up a small-sized market of approximately 54
billion won, estimated to include 40 billion won in cord
blood storage and 14 billion won in medicine, and the
market of the consumables and instrument sector in
which scaffold technology is included is reported as not
being formed [25].Table 2 World market analysis and prospects of stem cells [1
2010 2011 2012 2013 20
Stem cells market ($m) 2,715 3,238 3,819 4,500 5,2
Annual growth (%) 19 18 18 16
CAGR (%)
Stem cells services ($m) 1,420 1,647 1,894 2,178 2,4
Annual growth (%) 16 15 15 13
CAGR (%)
Cord blood banking ($m) 1,120 1,344 1,572 1,824 2,0
Annual growth (%) 20 17 16 13
CAGR (%)
Stem cell therapies ($m) 125 194 296 439 623
Annual growth (%) 55 53 48 42
CAGR (%)
Bone marrow transplants ($m) 50 53 56 59 62
Annual growth (%) 6 6 5 5
CAGR (%)Through these results, we can estimate that the
Korean stem cell market size is about 4.9% of the world
market, and this percentage can also be applied to the
scaffold element technology market (Figure 1).
If we use the data above to estimate the market size
and prospects of the Korean and world scaffold element
technology markets, the world scaffold element technol-
ogy market was approximately 457 million dollars in
2013, and by growing 13.4% annually, the market will
expand to 1.063 billion dollars in 2020. The Korean scaf-
fold element technology market was 22 million dollars
in 2013, and through a steady increase of 13.4% like the
world annual average growth rate, it is prospected to be
52 million dollars in 2020. In the last three years, the
sales growth rate of the same industry, medical materials
and medicine was 6.3%, which is 2.2% higher than the
4.1% of the last three years’ average economic growth
rate, and the average estimated sales growth rate for the
next 5 years of the market in which the evaluation tech-
nology is included is 13.4%. As it exceeds the recent
average economic growth rate of 4.1%, it is judged that
the growth possibility of the scaffold element technology
market is high (Table 4).Relevant industry trend
Though approximately 500 companies are participating in
the tissue engineering field worldwide, these companies
are very difficult to identify precisely due to frequent
change in company names, mergers, and acquisitions. Of
the approximately 500 companies, about 303 of them are
located in the US, the UK, Germany, Japan, or Sweden.
About 230 companies are closely related to regenerative]
14 2015 2016 2017 2018 2019 2020 2021
08 6,006 6,877 7,747 8,658 9,551 10,471 11,380
15 14 13 12 10 10 9
16.8 10.6
62 2,782 3,115 3,427 3,770 4,109 4,479 4,882
13 12 10 10 9 9 9
14.0 9.4
61 2,288 2,517 2,743 2,963 3,200 3,424 3,629
11 10 9 8 8 7 6
14.4 7.6
872 1,177 1,507 1,854 2,169 2,494 2,794
40 35 28 23 17 15 12
45.3 18.9
64 67 70 72 73 75 75
4 4 4 3 2 2 1
5.0 2.4
Table 3 Cell treatment market size and prospects (unit: 100 million dollars) [24]
Technology 2005 2010 2015 CAGR
Stem cells 20 52 109 18.5%
Cord blood 5 10 23 16.5%
Tissue engineering 69 135 232 12.9%
Transfusion products 128 224 350 10.6%
Cell-based gene therapy 15 30 59 14.7%
Capsule cell treatment 4 19 31 22.7%
Cell-based cancer vaccines 9 16 29 12.4%
Heteroplastids 6 19 32 18.2%
Element technology(Cell lines, cell culture fluid, cell carriers) 20 57 98 17.2%
Total 276 562 963 13.3%
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on the discovery and development of drugs using stem
cells, while another 27 companies are focusing on applica-
tion programs. Therefore, 148 companies are developing
biomaterials such as scaffolds, showing that it is not a
small number compared to the total number of tissue en-
gineering companies.
Along with developing biomaterials, some companies
are combining stem cells to develop tissue engineering
products for each tissue. Seventy-three companies are
investigating how to develop tissue engineering prod-
ucts. The areas of competitive activity are the US and
the UK, and there is a severe variability between the
companies in these areas. It is especially difficult to iden-
tify the relevant companies in the US due to changes in
company names Generally, large public companies are










Stem cell CAGR('12 ~ '20) : 39.7%
Tot
Figure 1 World market prospects of stem cells [25].are sufficiently performing the core activity, and some
companies are devoting their efforts to developing target
products in the new business field [18].
Companies and research institutes related to tissue en-
gineering share more knowledge and information and
promote industrial development when they concentrated
nationally or geographically to form a strong cluster.
When we look at the geographic distribution of tissue
engineering firms and research institutes (Figure 2), the
US is the highest with 52%, followed by Germany (21%),
Japan (16%), the UK (7%), and Sweden (4%) [18].
In Korea, there are no companies selling scaffold prod-
ucts, but there are R&D results. In 2012, The Korea
University mechanical engineering department research
team used micro-fluid technology to fix the extracellu-
lar matrix such as collagen to succeed in developing the










(Unit: 100  million dollars , year)
Table 4 Korean and world scaffold element technology market size and prospects (unit: million dollars)
Division 2012 2013 2014 2015 2016 2017 2018 2019 2020 CAGR (‘12~’20)
World stem cell market 3,819 4,500 5,208 6,006 6,877 7,747 8,658 9,551 10,471 13.4%
World scaffold element technology market (×10.15%) 388 457 529 610 698 786 879 969 1,063
Korean scaffold element technology market (×4.9%) 19 22 26 30 34 39 43 48 52
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companies related to three-dimensional cell culture, and
among them, BD Biosciences has the highest awareness,
followed by Life Technologies(Invitrogen), Corning, 3D
Biotek, and Insphero.Also, among the companies related
to three-dimensional cell culture consumables and instru-
ments, BD Biosciences is the largest with a 27% market
share, followed by Life Technologies(Invitrogen) (16%),
Corning (11%), Sigma-Aldrich (8%), Lonza(6%), Insphero
(4%), 3D Biotek(4%), and Global Cell Solutions (3%), show-
ing that there are many companies competing (Table 5 and
Figure 3).
The following are world cell and tissue suppliers, rep-
resented by American Type Culture Collection(ATCC),
Asterand plc, BioE, Life technologies, Cell Systems
Biotechnologie Vertrieb GmbH, and Lonza Group Ltd.,
and they supply cell-based products for the cell ther-
apy product and various human and animal cells or tis-
sues (Table 6).
The front industry companies of the scaffold market for
stem cells will be specialized companies, institutions and
general hospitals developing cell therapy products. Korean
cell-therapy-product-related companies are Anterogen,
Medipost, Cha Biotech, Pharmicell, SewonCellontech, and
Tegoscience. Table 7 shows the Korean companies who de-
veloped cell therapy product approved by the FDA in US
as well as their products. Also, 44 hospitals including Seoul
ASAN Medical Center, Severance Hospital, Samsung
Medical Center, Seoul National University Hospital,




Figure 2 Geographic distribution of tissue engineering firms in majorAround the world, there are many major companies
developing stem cell products such as Osiris Therapeu-
tics, NuVasive, Aastrom Biosciences, BrainStorm Cell
Therapeutics, Genzyme, International Stem Cell, Medcell
Biosciences, Medistem, Opexa Therapeutics, Plureon,
Revicor and StemCyte. Many of them are forming part-
nerships with pharmaceutical companies, and most of
them are known to be producing products for the treat-
ment of burns, wounds and skeletal defects (Table 8).
Conclusions
There can be differences in industrial prospects depend-
ing on the market and product scope of stem cells, but
in most of the global market analysis report, rapid
growth of the stem cell market is prospected.
Through the positive influences of unfulfilled medical
markets for treatment for diseases such as leukemia and
nervous system diseases and active stem cell research
support by the government, stem cell bank services, and
the activation of medical tourism, growth in stem-cell-
related industries is expected. However, there are factors
hindering the industrial activation such as high treat-
ment cost and government regulation due to ethical
concerns, but opportunity factors such as the continu-
ous increase of neurodegenerative diseases such as Par-
kinson’s disease, the growth of emerging countries such
as India and China, and the increase of availability on
new drug development are prospected to lead to growth
in the stem cell industry.
Therefore, the biomaterials included in the element







Table 5 Most purchased from suppliers of 3D cell culture consumables and instruments [26]
Company Primary supplier Secondary supplier % of all selections Total no. of selections
3D Biomatrix 0% 3% 2% 2
3D Biotek 1% 6% 4% 5
BD Biosciences 41% 11% 27% 35
Bellbrook Labs 0% 2% 1% 1
CellASIC 3% 0% 2% 2
CELLnTEC 1% 3% 2% 3
Corning 9% 14% 11% 15
Electrospinning Company 0% 0% 0% 0
EMD-Millipore 3% 2% 2% 3
Global Cell Solutions 4% 2% 3% 4
GlycosanBiosystems 0% 2% 1% 1
Hamilton Company 0% 2% 1% 1
Insphero 4% 3% 4% 5
InvivoSciences 0% 2% 1% 1
Kuraray 0% 0% 0% 0
Life Technologies (Invitrogen) 16% 16% 16% 21
Lonza 3% 10% 6% 8
MatTek 3% 2% 2% 3
Microtissues 0% 0% 0% 0
OrganDot 3D 0% 0% 0% 0
QGel Bio 0% 0% 0% 0
RealBio Technology 0% 0% 0% 0
RegeneMed 1% 1% 1% 1
Reinnervate 1% 2% 2% 3
Scivax 3% 2% 2% 2
Sigma-Aldrich 4% 8% 8% 11
Synthecon 1% 2% 2% 2
TAP Biosystems 0% 1% 1% 1
Tissue Growth Technologies 0% 0% 0% 0
ThermoScientific 0% 2% 2% 2
Zyoxel 0% 0% 0% 0
Total 69 63 132 132
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field expected to expand in its market together with the
growth of the front industry. The market size of three-
dimensional cell culture related consumables was esti-
mated to grow at an annual average rate of 23.5% from
34 million dollars in 2011 to 64 million dollars in 2014,
and it is prospected to grow strongly after 2014 [26].
Also, as results of the market research of industries re-
lated to stem cells and regenerative medicine to estimate
the Korean and world scaffold market sizes, the 2013
world scaffold element technology market was 457 mil-
lion dollars and expected to grow 13.4% annually, result-
ing in an expansion to 1.063 billion dollars in 2020. TheKorean scaffold element technology market was about
22 million dollars in 2013 and is expected to have a
steady growth of 13.4%, the same as the world annual
average growth rate, which would result in a market size
of 52 million dollars by 2020. By comparing with growth
rate of medical materials and medicine sales, the future
scaffold element technology market is judged to be
higher in growth possibility.
The scaffold market is in the initial market stage of re-
search and technology development progressing actively,
and market is difficult to identify accurately due to the
frequent M&A by the companies in the market and many



















(all less than 2%)
20%
Figure 3 Estimated supplier share of 3D consumables and instruments market [26].
Table 6 Selected suppliers of cells and tissues [18]
Company Product
American Type Culture Collection
(ATCC)
Supplies many types of cells lines and bioproducts.
Asterand plc Provides human biomaterials for drug testing(human primary cells and cell lines, RNA, tissue microarrays, frozen
and fixed human tissues)
ATCC-LCG Promochem
Partnership
Facilitates distribution of ATCC culture and bioproducts to life science researchers in Europe
BioE, Multi-Lineage Progenitor cellTM, a human umbilical cord blood-derived, clonal, multipotent stem cell line; unique
cell reagents.
Life Technologies Keratinocytes and other epithelial cells, endothelial cells, fibroblasts, etc.
Cascade Biologics Keratinocytes and other epithelial cells, endothelial cells, fibroblasts, etc.
Cell Systems Biotechnologie
Vertrieb GmbH
Cell biology products including human primary cells, 3D skin cell systems, and cell models for angiogenesis,
blood-barrier, and inhalation toxicology.
Lonza Group Ltd. Primary human and animal cells with customized media systems, Clonetics® and Poietics® Cell Systems.
Musculoskeletal Transplant
Foundation(MTF)
Pieces of human bone, skin, and other tissues; FlexHD, an acellular dermal matrix, primarily for surgery.
National Cancer Institute(NCI) Tissues, cell lines, databases, arrays, etc. primarily for cancer research.
National Cell Culture Center
(NCCC)
Division of Biovest International; provides customized, large-scale cell culture services.
National Disease Research
Interchange(NDRI)
Human tissues, organs, and derivatives for research.
National Stem Cell Bank(NSCB) at
WiCell
Established to acquire, characterize and distribute the 21 human embryonic stem cell lines and their sub-clones
to federally funded research programs; they currently have 13 of the 21 cell lines in the federal registry.
NIH Human Embryonic Stem Cell
Registry
Lists the derivations of stem cells that are eligible for federal funding and provides contact information for
acquiring the cell lines.
OnCore UK Human specimens for cancer research
ProBioGen AG Specializes in mammalian cell engineering and cell culture: design of custom immortalized cell lines for vaccine
and protein production, or for other customer needs.
SciKon Innovation, Inc. Human matrix cell culture surface; human stellates; human hepatocyte cryopriserved cells.
Tebu-bio laboratories Various cryopreserved primary cells; cell biology services such as cell amplification, differentiation, transfection,
mycoplasma testing; establish cellular models overexpressing of silencing a protein of interest.
Zen Bio Human adult stem cells, preadipocytes, adipocytes, primary human hepatocytes; specialized media.
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Table 7 Cell therapy products approved in South Korea [18]
Company Product Indication
Anterogen Adipocel Adipose stem cell
Cupistem® Adipose stem cell
Queencell® Autologous Mesenchymal stem cell
Sewon
Cellontech
RMS ossron Cartilage cell
Chondron Bone stem cell
Chabiotech Hyalograft-3D+ Autologous skin fibroblasts
Autostem Adipose cell
Creagene Creavax-RCC+ Dendritic cell
FCB-Pharmicell Heartcellgram-
AMI
Autologous Bone Marrow-Derived Mesenchymal stem cell
Green Cross cell Immuncell-LC® Adjuvant therapy for patients whose tumor has been removed after curative resection for Hepatocellular
Carcinoma
MCTT KERAHEALTM Human epidermal keratinocyte
Medipost Cartistem® Human umcilical cord blood-derived mesenchymal stem cell product for cartilage regeneration
S-Bio Medics Cureskin Autologous fibroblast therapy
Tegoscience Holoderm® Epidermal cell
Kaloderm® Epidermal cell
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in Korea and in other parts of the world, are actively con-
ducting research to develop scaffolds for regenerative
medicine that can perform a similar role as the extracellu-
lar matrix, and policies and systems on stem cells andTable 8 Leading commercial cell therapy products and compa
Company Product
Advanced Biohealing, a Shire Company Dermagraft





BioDlogics(distributed by America) BioDfentor
BioDlogics(distributed by America) BioDfence
Dendreon Provenge
Fibrocell laVin
Genzyme(a Sanofi company) Carticel
Genzyme(a Sanofi company) Epicel







Zimmer Orthobiologics DeNovo NTregenerative medicine are quickly expanding and being
established cross-nationally for the quick commercia-
lization of products. Therefore, the future prospects of the
stem cells and regenerative medicine industry and other








Wound healing, soft tissue defects, skeletal defects
Wound healing, soft tissue defects, skeletal defects
Prostate cancer
Nasolabial fold wrinkles(smile lines)
Articular cartilage repair
Severe burn and skin replacement
Articular cartilage repair
Wound healing, soft tissue defects, skeletal defects
Venous leg ulcers, diabetic foot ulcers
Gingival and alveolar mucosal surface defects
Musculoskeletal defects
Acute and chronic wounds
Articular cartilage repair
Articular cartilage repair
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